Table 3: Time to onset and resolution of irAEs in phase III and pooled phase II trials [25].

Phase III MDX010-20
Ipilimumab 3 mg/kg ( = 131)
Pooled phase II data
Ipilimumab 3 mg/kg ( = 111)

irAE time to onset
 Grade 2–5, 4538
 Median, weeks (95% CI)6.14 (3.71–8.14)6.93 (4.86–7.57)
 % of patients experiencing irAE within
  0–1 month4232
  >1–3 months4463
  >3–5 months75
  >5 months70
irAE time to resolution
 Grade 2–4, 4438
 Resolved, 3323
 Median, weeks (95% CI)6.86 (4.14–8.43)5.71 (2.14–NR)
 % of patients whose irAE resolved within
  0–1 month5274
  >1–3 months3617
  >3–5 months99
  >5 months30

CI: confidence interval; irAE: immune-related adverse event; NR: not reached.